Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Elan Corporation recently provided an update on its strategic plans for the future. The company plans several acquisitions and has other strategic initiatives lined up for further advancement.

Elan is set to acquire privately held AOP Orphan Pharmaceuticals (“AOP”), for an upfront payment of €263.5 million (cash of €175.7 million and Elan ordinary shares of €87.8 million) plus regulatory milestone payments of up to €270 million.

AOP focuses on developing innovative drugs for orphan indications in areas like hematology & oncology, cardiology & pulmonology, neurology, and metabolic disorders. AOP currently has four late-stage candidates in its portfolio. In 2012, AOP recorded revenues of around €59 million (approximately $76 million).

Additionally, Elan intends to buy 48% shares of Newbridge Pharmaceuticals, another privately held company, for $40 million. Elan also has the option to buy the remaining stake in Newbridge Pharma for $244 million by 2015.

Newbridge Pharma focuses on in-licensing deals, acquisitions, registering and commercializing approved products (pharmaceuticals and biologics) in areas like oncology, immunology, metabolic disorders, gastrointestinal and central nervous system.

Apart from acquisitions, Elan also has plans to divest its pipeline candidate, ELND005, to an independent company, Speranza Therapeutics. Speranza will be responsible for the future development of the candidate. ELND005 is currently under development for the treatment of agitation/aggression in Alzheimer’s disease, and Downs Syndrome.

Elan will be making an upfront payment of $70 million to Speranza for an 18% minority equity position. Speranza is also expected to receive up to $8 million in future. Additionally Speranza will receive royalties in major markets along with additional milestones, and will retain commercial rights in certain areas.

The ELND005 divestiture will help the company cut down operating expenses related to the development of the candidate. The company expects to cut its operating expenses guidance of $170−$190 million by around $35 million to $45 million.

We note that Elan recently inked a deal with Theravance Inc. (THRX - Analyst Report) to purchase a participation interest in potential future royalty payments for a one-time cash payment of $1.0 billion. Elan is expected to receive a 21% participation interest in potential future royalty payments that Theravance would likely to receive from GlaxoSmithKline (GSK - Analyst Report) from four respiratory programs.

Moreover, the company announced a debt offering of $800 million to optimize its capital structure and maintain its strategic flexibility and significant cash balance. Elan also announced a $200 million share repurchase program.

The transactions will go through upon approval from Elan’s shareholders after the company’s Extraordinary General Meeting in June this year.

Meanwhile, Royalty Pharma recently raised its offer for Elan to $12.50 per share in cash from the previous offer of $11.25 per share. Royalty Pharma’s raised offer however does not include the $1.00 per share net cash right that was there in its previous offer. Elan’s Board will assess Royalty Pharma’s offer and will advise its shareholders accordingly.

We believe that the ELND005 divestiture is encouraging. The company will be able to reduce its operating expenses to some extent. However, we have very low visibility on the products that will be added to Elan’s portfolio as a result of the acquisitions.

Elan presently carries a Zacks Rank #2 (Buy). Jazz Pharmaceuticals Public Limited Company (JAZZ - Analyst Report) currently looks better positioned with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%